
ENOV — Enovis Corp
NYSE · Healthcare · Medical Devices
$20.64
+$0.11 (+0.56%)
Enovis Corp (ENOV) is a medical devices company listed on NYSE. It is led by Damien McDonald, based in 2711 Centerville Road, Wilmington, DE, United States, 19808, with about 7,802 employees. Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Latest reported ENOV revenue for 2025-10-03 was $548.9M. Net income was -$570.9M. Revenue was down 2.8% from 2025-07-04 to 2025-10-03. ENOV currently screens at market cap $1.37B.
Use this ENOV page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ENOV quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ENOV SEC filings page. Lician reads the product cache first so this HTML stays unique to Enovis Corp even when a live quote feed is slow.
About Enovis Corp
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
ENOV Key Statistics
Market Cap
$1.37B
Volume
175,509
Previous Close
$25.21
Day Range
$24.68 – $25.53
EPS
-$14.93
Revenue
$2.11B
Net Income
-$824.82M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+23.5%
Profit Margin
-39.1%
Employees
7,802
ENOV Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $2.11B | $1.71B | $408.71M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$824.82M | -$32.73M | -$11.76M |
| EPS (Diluted) | -$14.93 | -$0.61 | -$0.71 |
Total Assets
$4.72B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$48.17M
Operating Cash Flow
$113.50M
Free Cash Flow
$0.00
Enovis Corp Company Information
- CEO & Director
- Damien McDonald
- Headquarters
- 2711 Centerville Road, Wilmington, DE, United States, 19808
- Website
- www.enovis.com
- Phone
- 302 252 9160
- IPO / Founded
- 2008-05-08
- Sector
- Healthcare
- Industry
- Medical Devices